Przejdź do zawartości
Merck

Characterization of multiple interactions between the envelope E protein of SARS-CoV-2 and human BRD4.

STAR protocols (2023-01-04)
Mohamad Zandian, Suk Min Jang, Catherine Lachance, Arpan Acharya, Siddappa N Byrareddy, Jacques Côté, Tatiana G Kutateladze
ABSTRAKT

The SARS-CoV-2 envelope (E) protein hijacks human BRD4 (bromodomain and extra-terminal domain protein 4). Here, we describe a protocol to characterize the interaction of the acetylated E protein with BRD4 in vivo. We detail steps to use NMR spectroscopy to map the binding interface and include steps to monitor the effect of BRD4 inhibitors in SARS-CoV-2-infected human lung bronchial epithelial cells. This approach could be applied to study interactions involving other viral and human proteins. For complete details on the use and execution of this protocol, please refer to Vann et al. (2022).1.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Millipore
ANTI-FLAG® M2 Affinity Gel, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
ANTI-FLAG® M2-Peroxidase (HRP) antibody, Mouse monoclonal, clone M2, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt dihydrate, BioUltra, 98.5-101.5%
Sigma-Aldrich
Bovine Serum Albumin, lyophilized powder, essentially globulin free, ≥99% (agarose gel electrophoresis)
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)